Cardiol Therapeutics

About:

Cardiol Therapeutics develops innovative cannabidiol medicines for heart disease.

Website: https://www.cardiolrx.com/

Twitter/X: cardiolrx

Top Investors: Canaccord Genuity Group, Raymond James, AlbaCore Capital, Echelon Wealth Partners

Description:

Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.

Total Funding Amount:

$76.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oakville, Ontario, Canada

Founded Date:

2017-01-01

Contact Email:

info(AT)cardiolrx.com

Founders:

David Elsley

Number of Employees:

11-50

Last Funding Date:

2021-11-03

IPO Status:

Public

Industries:

© 2025 bioDAO.ai